Systemic Malassezia furfur infections in patients receiving intralipid therapy.
Systemic infection with Malassezia furfur was first reported in 1981 as a specific complication of Intralipid therapy in a neonate. Six additional patients, including three older than 16 years of age, were identified subsequently. All had received prolonged Intralipid infusion through central venous catheters. Pulmonary infection was documented in tissue in three cases, the clinical presentation was characterized by pulmonary infiltrates, fever, and, in the infants, thrombocytopenia. Two subgroups of patients appear to be at the greatest risk for Malassezia infection: neonates with cardiopulmonary disease and adults with severe gastrointestinal disease and immunosuppression. The documentation of pulmonary arterial lipid deposits in vessels that had been infiltrated by Malassezia organisms and the observation of organisms in small pulmonary thromboemboli suggest that these lipophilic and lipid-dependent organisms are introduced into the bloodstream from venous catheters and require high lipid concentrations to proliferate in tissue.
D000293:Adolescent; D002675:Child, Preschool; D005217:Fat Emulsions, Intravenous / Q000009:adverse effects*; D005260:Female; D006801:Humans; D008171:Lung Diseases / Q000209:etiology / Q000382:microbiology / Q000473:pathology; D008290:Malassezia; D008297:Male; D008875:Middle Aged; D009181:Mycoses / Q000209:etiology* / Q000382:microbiology
D005217:Fat Emulsions, Intravenous